 reuters    president donald trump told congress on tuesday that more needs to be done to bring down  artificially high  prices for prescription drugs  while at the same time praising a drug that turns out to cost    per year  during the televised address  trump acknowledged in the audience megan crowley  a college student who has pompe disease   a rare muscle disorder that can be treated with an expensive enzyme replacement therapy    but our slow and burdensome approval process at the food and drug administration keeps too many advances  like the one that saved megan s life  from reaching those in need   the president said   if we slash the restraints  not just at the fda but across our government  then we will be blessed with far more miracles like megan   trump has in the past excoriated drugmakers for charging  astronomical  prices  while acknowledging how  complicated  the nation s healthcare system is  representatives of the trump administration could not immediately be reached for comment on wednesday on whether the president believes the treatment price for pompe disease is fair   trump s comments on tuesday night highlight an issue central to the industry and investors   the potential for deregulation of the fda  the agency charged with approving pharmaceutical products   i think trump used this example somewhat cynically as a way of trying to advance the deregulatory agenda   said dr  aaron kesselheim  a researcher at harvard medical school   the fda s standards actually promote innovation because patients don t want just any old drug   they want drugs that work   megan s father  john crowley  now chief executive at amicus therapeutics inc  started a biotech company in  to seek a treatment for pompe disease   in   the fda   after a nine month review   approved infused enzyme replacement therapy myozyme for patients born with the condition  a similar drug  lumizyme  was approved in  for late onset pompe disease and is now used regardless of a patient s age   the average annual cost of treatment is     according to paris based sanofi sa  which now owns the drugs  under the orphan drug act of   drugs for rare diseases   defined as those that treat fewer than   patients   are given a range of incentives including seven years of marketing exclusivity      pharmaceutical companies know they get a free pass for very expensive drugs for orphan diseases  whereas they don t for mainstream diseases   said joel hay  professor of pharmaceutical economics and policy at the university of southern california  the national organization for rare disorders  nord  applauded trump s recognition  but disagreed with the idea that the regulatory process needs an overhaul       our patients deserve the same quality therapies as everyone else  and to weaken the standards will only threaten our population with unsafe  ineffective therapies   nord said in a statement on wednesday       pompe disease  affecting   to   people worldwide  prevents the body from making enough of an enzyme used by heart and muscle cells to convert a form of sugar called glycogen into energy  when glycogen builds up in these cells it can lead to disability and death  nord estimates that around  million americans suffer from   rare diseases   